Department of Cardiology, Heart Center, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Department of Cardiology, Copenhagen University Hospital Gentofte, Kildegårdsvej 28, 2900 Hellerup, Denmark.
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):347-355. doi: 10.1093/ehjcvp/pvz038.
Various drugs increase the risk of out-of-hospital cardiac arrest (OHCA) in the general population by impacting cardiac ion channels, thereby causing ventricular tachycardia/fibrillation (VT/VF). Dihydropyridines block L-type calcium channels, but their association with OHCA risk is unknown. We aimed to study whether nifedipine and/or amlodipine, often-used dihydropyridines, are associated with increased OHCA risk, and how these drugs impact on cardiac electrophysiology.
We conducted a case-control study with VT/VF-documented OHCA cases with presumed cardiac cause from ongoing population-based OHCA registries in the Netherlands and Denmark, and age/sex/index date-matched non-OHCA controls (Netherlands: PHARMO Database Network, Denmark: Danish Civil Registration System). We included 2503 OHCA cases, 10 543 non-OHCA controls in Netherlands, and 8101 OHCA cases, 40 505 non-OHCA controls in Denmark. To examine drug effects on cardiac electrophysiology, we performed single-cell patch-clamp studies in human-induced pluripotent stem cell-derived cardiomyocytes. Use of high-dose nifedipine (≥60 mg/day), but not low-dose nifedipine (<60 mg/day) or amlodipine (any-dose), was associated with higher OHCA risk than non-use of dihydropyridines [Netherlands: adjusted odds ratios (ORadj) 1.45 (95% confidence interval 1.02-2.07), Denmark: 1.96 (1.18-3.25)] or use of amlodipine [Netherlands: 2.31 (1.54-3.47), Denmark: 2.20 (1.32-3.67)]. Out-of-hospital cardiac arrest risk of (high-dose) nifedipine use was not further increased in patients using nitrates, or with a history of ischaemic heart disease. Nifedipine and amlodipine blocked L-type calcium channels at similar concentrations, but, at clinically used concentrations, nifedipine caused more L-type calcium current block, resulting in more action potential shortening.
High-dose nifedipine, but not low-dose nifedipine or any-dose amlodipine, is associated with increased OHCA risk in the general population. Careful titration of nifedipine dose should be considered.
各种药物通过影响心脏离子通道,导致室性心动过速/颤动(VT/VF),从而增加普通人群中心脏骤停(OHCA)的风险。二氢吡啶类药物可阻断 L 型钙通道,但它们与 OHCA 风险的关联尚不清楚。我们旨在研究硝苯地平(nifedipine)和/或氨氯地平(amlodipine)这两种常用的二氢吡啶类药物是否与 OHCA 风险增加相关,以及这些药物如何影响心脏电生理学。
我们进行了一项病例对照研究,纳入了来自荷兰和丹麦正在进行的基于人群的 OHCA 登记处的 VT/VF 记录 OHCA 病例(假定为心脏原因),以及年龄/性别/索引日期匹配的非 OHCA 对照(荷兰:PHARMO 数据库网络,丹麦:丹麦民事登记系统)。我们纳入了 2503 例 OHCA 病例和 10543 例非 OHCA 对照(荷兰),8101 例 OHCA 病例和 40505 例非 OHCA 对照(丹麦)。为了研究药物对心脏电生理学的影响,我们在人诱导多能干细胞衍生的心肌细胞中进行了单细胞膜片钳研究。与未使用二氢吡啶类药物相比,高剂量硝苯地平(≥60mg/天)而非低剂量硝苯地平(<60mg/天)或氨氯地平(任何剂量)的使用与更高的 OHCA 风险相关[荷兰:调整后的比值比(ORadj)为 1.45(95%置信区间 1.02-2.07),丹麦:1.96(1.18-3.25)]或使用氨氯地平[荷兰:2.31(1.54-3.47),丹麦:2.20(1.32-3.67)]。在使用硝酸盐或有缺血性心脏病史的患者中,高剂量硝苯地平的使用并未进一步增加(OHCA)风险。硝苯地平和氨氯地平以相似的浓度阻断 L 型钙通道,但在临床使用浓度下,硝苯地平引起更多的 L 型钙电流阻断,导致动作电位缩短更多。
高剂量硝苯地平(nifedipine)而非低剂量硝苯地平或任何剂量氨氯地平与普通人群中 OHCA 风险增加相关。应考虑仔细调整硝苯地平的剂量。